Takeda Pharmaceutical Company (TAK)
NYSE:TAK
Want to see TAK full AI Analyst Report?
TAK Stock Chart & Stats
$14.08
-$0.09(-0.67%)
At close: 4:00 PM EST
$14.08
-$0.09(-0.67%)
Day’s Range― - ―
52-Week Range$12.99 - $18.90
Previous CloseN/A
Volume1.19M
Average Volume (3M)3.05M
Market Cap
$50.95B
Enterprise Value$12.34T
Total Cash (Recent Filing)$597.63B
Total Debt (Recent Filing)$4.90T
Price to Earnings (P/E)41.7
Beta0.05
Next Earnings
Jul 30, 2026EPS Estimate
0.19Next Dividend Ex-DateN/A
Dividend Yield3.86%
Share Statistics
EPS (TTM)61.44
Shares Outstanding3,182,525,000
10 Day Avg. Volume3,230,951
30 Day Avg. Volume3,045,898
Financial Highlights & Ratios
PEG Ratio0.52
Price to Book (P/B)1.19
Price to Sales (P/S)1.94
P/FCF Ratio11.45
Enterprise Value/Market Cap242.16
Enterprise Value/Revenue2.71
Enterprise Value/Gross Profit4.64
Enterprise Value/Ebitda8.65
Forecast
1Y Price Target
$21.00Price Target Upside49.15% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.46
Revenue Forecast (FY)$29.23B
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessBoth studies met all primary and secondary endpoints demonstrating statistically significant improvement across a broad range of NT1 symptoms compared to placebo.
Drug DevelopmentTakeda is preparing to launch 3 new drugs that could bolster the long-term outlook.
Pipeline ExpansionIBI363 and IBI343 were recently added to Takeda's pipeline, bringing compelling oncology assets.
Bears Say
Marketing StrategyTakeda currently does not have a strong candidate product suitable for direct-to-consumer strategies.
Pricing ChallengesMany EU governments and the UK believe they are already paying fair prices and may eschew access if their health economic math does not work.
Tariff ExposureTakeda has very limited tariff exposure and therefore less incentive to negotiate directly with the US government.
Takeda Pharmaceutical Company News
TAK FAQ
What was Takeda Pharmaceutical Company’s price range in the past 12 months?
Takeda Pharmaceutical Company lowest stock price was $12.99 and its highest was $18.89 in the past 12 months.
What is Takeda Pharmaceutical Company’s market cap?
Takeda Pharmaceutical Company’s market cap is $50.95B.
When is Takeda Pharmaceutical Company’s upcoming earnings report date?
Takeda Pharmaceutical Company’s upcoming earnings report date is Jul 30, 2026 which is in 61 days.
How were Takeda Pharmaceutical Company’s earnings last quarter?
Takeda Pharmaceutical Company released its earnings results on May 13, 2026. The company reported -$0.049 earnings per share for the quarter, beating the consensus estimate of -$0.075 by $0.026.
Is Takeda Pharmaceutical Company overvalued?
According to Wall Street analysts Takeda Pharmaceutical Company’s price is currently Undervalued.
Does Takeda Pharmaceutical Company pay dividends?
Takeda Pharmaceutical Company pays a Semiannually dividend of $0.321 which represents an annual dividend yield of 3.86%. See more information on Takeda Pharmaceutical Company dividends here
What is Takeda Pharmaceutical Company’s EPS estimate?
Takeda Pharmaceutical Company’s EPS estimate is 0.19.
How many shares outstanding does Takeda Pharmaceutical Company have?
Takeda Pharmaceutical Company has 3,182,525,000 shares outstanding.
What happened to Takeda Pharmaceutical Company’s price movement after its last earnings report?
Takeda Pharmaceutical Company reported an EPS of -$0.049 in its last earnings report, beating expectations of -$0.075. Following the earnings report the stock price went up 1.34%.
Which hedge fund is a major shareholder of Takeda Pharmaceutical Company?
Currently, no hedge funds are holding shares in TAK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Takeda Pharmaceutical Company Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$21.00 (49.15% Upside)
$21.00 (49.15% Upside)
Blogger Sentiment
Bullish
TAK Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 562.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 2.7%
Last 30 Days <0.1%
Last 30 Days <0.1%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
7.83%
12-Months-Change
Fundamentals
Return on Equity
2.61%
Trailing 12-Months
Asset Growth
1.94%
Trailing 12-Months
Company Description
Takeda Pharmaceutical Company
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan, the United States, Europe, Canada, Latin America, Russia, rest of Asia, and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab, Alofisel, Dexilant, Natpara, Adynovate/Adynovi, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Velcade, Leuplin/Enantone, Adcetris, Vyvansese, Trintellix, and Alunbrig brands. Takeda Pharmaceutical Company Limited has out-licensing agreement with Neurocrine Biosciences, Inc.; collaborations and in-licensing agreements with the University of Texas MD Anderson Cancer Center, Arrowhead Pharmaceuticals Inc., and Ovid Therapeutics Inc.; and collaboration with Evox Therapeutics Ltd., as well as a licensing agreement with ProThera Biologics Inc. It also has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, Selecta Biosciences, BridGene Biosciences, Skyhawk Therapeutics, and StrideBio; and strategic alliances with Egle Therapeutics SAS; Evotec SE; Neurocrine Biosciences, Inc.; Carmine Therapeutics; KSQ Therapeutics; and Anima Biotech. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan.
TAK Company Deck
TAK Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call balanced strong R&D momentum, significant clinical successes and robust cash generation against near-term revenue pressures from VYVANSE loss of exclusivity, pricing and supply dynamics in plasma-derived therapies, and substantial transformation and launch investments that will weigh on FY2026 profit and EPS. Management presented a clear two‑horizon strategy: near-term transformation and investment to enable a wave of launches (Horizon One) followed by accelerated growth as the new products scale (Horizon Two). The pipeline success (3 positive Phase IIIs, priority reviews, TAK-881 data), disciplined cost savings (~JPY 300 billion captured to date) and solid free cash flow provide a foundation to absorb short-term headwinds and fund launches, while execution risks (resizing, restructuring costs, biosimilar/patent challenges and market dynamics in plasma products) are material but appear managed. Overall, positives from the pipeline and balance sheet outweigh the near-term financial and operational challenges, supporting a constructive outlook conditional on successful commercialization execution.View all TAK earnings summariesTAK Stock 12 Month Forecast
Average Price Target
$21.00
▲(49.15% Upside)
Technical Analysis
Dr Reddy's Laboratories
―
Viatris
―
Neurocrine
―
Teva Pharmaceutical
―
Haleon PLC Sponsored ADR
―
Ownership Overview
0.10% Insiders
0.61% Mutual Funds
1.19% Other Institutional Investors
97.93% Public Companies and
Individual Investors